Cerebain Biotech Corporation (OTC:CBBT) announced on Wednesday that PKG Inc is to become the key manufacturer for ClearMask LLC and Xometry.
ClearMask is the first FDA-cleared, fully transparent surgical mask suitable for hospitals, clinics, schools, retail, hospitality and other settings. The mask meets applicable ASTM Level 3 requirements for fluid resistance and flammability.
To meet the rigorous controls necessary for FDA-cleared products, ClearMask and Xometry, a marketplace for on-demand manufacturing, have partnered with PKG's ISO 13485-certified facility to manufacture the FDA-cleared version of the ClearMask.
PKG has started a new production floor designed to support the mass production of the clear face mask.
Over the next few weeks, PKG Inc intends to fully transition company ownership to Cerebain Biotech Corporation in an acquisition that began in the middle of this year.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial